NEW YORK, Sept 14 - Third Wave Technologies said Thursday it had reached an agreement to provide Imperial College of Great Britain, Royal Brompton's Hospital, and the UK National Health Service Trust with access to its Invader operating system for SNP detection and gene expression analysis.

Under the terms of the deal, Third Wave of Madison, Wis., will provide the institutions with preferred access to its pharmacogenomic assays as well as offer additional support for their genomics research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.